Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Breast Cancer
Phase NA
Enrollment 120
Locations 25 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to assess whether expression of not only POLQ/Polθ, but also Shieldin complex and/or 53BP1 are correlated with primary and/or acquired resistance to PARPi (Poly(ADP-Ribose) Polymerases inhibitors) in a sub-population of locally advanced or metastatic breast cancer patients and vary regarding type and location of gBRCA1/2 mutations. This translational research program is composed of two multicentric, non-randomized prospective studies in patients with HER2-negative locally advanced or metastatic breast cancer: * The main study concerns 80 patients eligible for PARPi (according to the investigators).PARPi treatments (talazoparib or olaparib) will be administered and dosed according to the standard of care administration. * The sub-study concerns 40 patients in progression disease under PARPi alone. For each included patient in the main study or sub-study, tumor biopsy specimen and blood samples will be collected at different times during the study.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Other: Main study: — For each included patient, tumor biopsy specimen and blood samples will be collected at baseline visit (before the first dose of PARPi treatment). During the treatment period: blood samples will be scheduled every 8 weeks (i.e. 2 cycles). At the time of progression: tumor biopsy and blood samples will be collected.
  • Other: Sub-study: — For each included patient, tumor biopsy specimen and blood samples will be collected as soon as possible after progression (before initiation of the post PARPi anti-tumoral treatment).

Primary Outcomes

  • Main study: the primary endpoint is the Area under the Receiver Operating Characteristic Curve (ROC Curve) of POLQ expression to identify patients presenting progressive disease or death at 6 months under PARPi alone (primary resistance). (6 months for each patient)
  • Sub-study: the primary end point is the rate of patients presenting loss of Shieldin complex and/or 53BP1. (1 month for each patient)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-06-23
Completion: 2027-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Institut Claudius Regaud
Contact Information
Study Contact:
Florence DALENC
05 31 15 51 04
Dalenc.Florence@iuct-oncopole.fr
Monica ARNEDOS
05 56 33 32 38
m.arnedos@bordeaux.unicancer.fr
Institut Bergonie
Georges EMILE
02 31 45 50 50
g.emile@baclesse.unicancer.fr
Centre Francois Baclesse
Interventions
  • Other: Main study: — For each included patient, tumor biopsy specimen and blood samples will be collected at baseline visit (before the first dose of PARPi treatment). During the treatment period: blood samples will be scheduled every 8 weeks (i.e. 2 cycles). At the time of progression: tumor biopsy and blood samples will be collected.
  • Other: Sub-study: — For each included patient, tumor biopsy specimen and blood samples will be collected as soon as possible after progression (before initiation of the post PARPi anti-tumoral treatment).
Study Locations (25 sites)
Institut Bergonie, Bordeaux, France
Centre Francois Baclesse, Caen, France
Centre Jean Perrin, Clermont-Ferrand, France
Centre Georges Francois Leclerc, Dijon, France
Centre Hospitalier Départemental Vendée, La Roche-sur-Yon, France
Centre Oscar Lambret, Lille, France
CHU de LIMOGES, Limoges, France
Centre Leon Berard, Lyon, France
Institut Paoli Calmettes, Marseille, France
Centre de Cancerologie Du Grand Montpellier, Montpellier, France
Eligibility Criteria
MAIN STUDY INCLUSION CRITERIA: 1. Women (or men) aged ≥ 18 years with histologically proven breast cancer 2. Metastatic relapse or locally advanced breast cancer 3. No-HER2 overexpression or amplification 4. Triple-negative (defines as ER\<1%, PR\<1% and HER2-negative as per ASCO CAP guidelines) or hormone receptor positive (defines as ER and/or PR ≥ 1%) breast cancer 5. Patients with metastases that can be biopsied except bone metastases. At baseline, if patients already have an archived biopsy from a secondary or a primary site (if stage IV) of their current disease, this material can be used for the study, provided that, it was collected within 3 months prior enrollment and a frozen and a FFPE sample are both available for research 6. ECOG Performance Status ≤ 2 7. Patients must have measurable or evaluable disease according to RECIST v1.1 8. Patient with deleterious germline BRCA 1 and/or 2 mutation, eligible for PARP inhibitor therapy (olaparib or talazoparib), according each investigator 9. Any number of prior lines therapy are allowed 10. Current treatment with PARP inhibitor not yet started 11. Women should be post-menopaused or willing to accept the use of an effective contraceptive regimen during the treatment period by PARP inhibitor 12. Patient able to participate and willing to give informed consent prior performance of any study-related procedures and to comply with the study protocol 13. Patient affiliated to a Social Health Insurance in France NON-INCLUSION CRITERIA: 1. Abnormal coagulation contraindicating biopsy 2. Bone metastases when this is the only site of biopsiable disease 3. Patients with all target in a previously irradiated region, except if clear progression has been observed prior to study in at least one of them 4. Patients with known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer 5. Patients with known untreated CNS metastases and/or carcinomatous meningitis 6. Patients with a known history of Human Immunodeficiency Virus (HIV) 7. Patients with known active Hepatitis B or C 8. Patients should not be on any other anti-cancer therapy (chemotherapy, endocrine therapy, immunotherapy, tailored therapy or alternative investigational therapy) 9. Patient pregnant, or breast-feeding 10. Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure 11. Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice) SUB-STUDY INCLUSION CRITERIA: 1. Women (or men) aged ≥ 18 years with histologically proven breast cancer 2. Metastatic relapse or locally advanced breast cancer 3. No-HER2 overexpression or amplification 4. Triple-negative (defines as ER\<1%, PR\<1% and HER2-negative as per ASCO CAP guidelines) or hormone receptor positive (defines as ER and or PR ≥ 1%) breast cancer 5. Patients with metastases that can be biopsied except bone metastases 6. ECOG Performance Status ≤ 2 7. Patients, with deleterious germline BRCA 1 and/or 2, in progression under PARPi alone (talazoparib or olaparib) 8. Patient able to participate and willing to give informed consent prior performance of any study-related procedures and to comply with the study protocol 9. Patient affiliated to a Social Health Insurance in France NON-INCLUSION CRITERIA: 1. Abnormal coagulation contraindicating biopsy 2. Bone metastases when this is the only site of biopsiable disease 3. Patient pregnant, or breast-feeding 4. Patients with a known history of Human Immunodeficiency Virus (HIV) 5. Patients with known active Hepatitis B or C 6. Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure 7. Patients already participating in the main REPARP study 8. Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice)
Conditions Breast Cancer
Phase NA
Enrollment 68
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

Currently, there are 3.5 million breast cancer survivors in the United States and this number is expected to increase dramatically. The proposed research will examine whether a novel exercise intervention for breast cancer patients who are undergoing chemotherapy protects against cardiovascular dysfunction. Findings may have implications for cardiovascular disease prevention in this population.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Exercise training — Exercise training performed at home under remote live supervision over 12 weeks while patients undergo chemotherapy for breast cancer.

Primary Outcomes

  • Change in brachial artery FMD (12 weeks)
  • Change in global longitudinal strain (12 weeks)
  • Feasibility, tolerability and safety of exercise training during breast cancer chemotherapy (Monitored throughout the 12 weeks of intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-04-05
Completion: 2027-01-31
Eligibility
Age: 18 Years – 85 Years
Sex: FEMALE
Volunteers: false
Enrollment: 68 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Florida
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigators:
  • Demetra Christou, PhD (PRINCIPAL_INVESTIGATOR) - University of Florida
Contact Information
Study Contact:
Demetra Christou, PhD
3522941746
ddchristou@ufl.edu
Eileen Handberg
352-273-9082
handbem@medicine.ufl.edu
Demetra Christou, PhD
352-294-1746
ddchristou@ufl.edu
Integrative Cardiovasculal Physiology Laboratory, University of Florida
Interventions
  • Behavioral: Exercise training — Exercise training performed at home under remote live supervision over 12 weeks while patients undergo chemotherapy for breast cancer.
Study Locations (1 sites)
Integrative Cardiovasculal Physiology Laboratory, University of Florida, Gainesville, Florida 32611 United States
Eligibility Criteria
Inclusion Criteria: * Active diagnosis of primary invasive non-metastatic breast cancer, stages I-III * Female * 18 to 85 years of age * Scheduled to initiate neoadjuvant or adjuvant chemotherapy (anthracycline, alkylating agent and/or taxane) * Absence of contraindications to exercise * Study clinician approval * Able to give consent * Informed consent obtained from the subject and documentation of subject agreement to comply with study-related process Exclusion Criteria: * Do not meet inclusion criteria * Receiving targeted therapies (CDK4/6 or PARP inhibitors) * Receiving radiation therapy concurrent with chemotherapy * Lymphedema stage ≥ 2 prior to study enrollment * Any relevant cardiovascular diseases (stroke, heart failure, myocardial ischemia during maximal graded exercise test, myocardial infarction, angina pectoris, coronary artery bypass surgery or angioplasty or coronary stent) * Current participation in other experimental interventions that may confound interpretation of study findings (e.g., dietary intervention for weight loss)
Conditions Breast Carcinoma
Phase NA
Enrollment 26
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

This clinical trial studies the effects of dietary white button mushroom on inflammation (the body's process of fighting against harmful things) and immune cells (white blood cells) in postmenopausal women with both high body mass index or BMI (percentage of body fat) and high risk of breast cancer. The body is in a constant state of alert when inflammation lingers at a low level and becomes chronic, as with having button mushroom is a dietary supplement that may improving responses of immune cells (white blood cells) and decreasing chronic inflammation. Information gathered from this study may help researchers determine whether white button mushroom have any effects on body fat and breast cancer risk.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Other: Questionnaire Administration — Ancillary studies
  • Drug: White Button Mushroom Extract — Given PO

Primary Outcomes

  • Relative change in levels of circulating myeloid-derived suppressor cells (MDSCs) within the peripheral blood mononuclear (PBMC) compartment (Baseline up to 3 months)
  • Relative change in immune cell composition within the peripheral blood mononuclear (PBMC) compartment (Baseline up to 3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-07-27
Completion: 2027-01-12
Eligibility
Age: 21 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 26 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Lisa D Yee (PRINCIPAL_INVESTIGATOR) - City of Hope Medical Center
Contact Information
Study Contact:
Lisa D. Yee
626-471-7100
lyee@coh.org
City of Hope Medical Center
Lisa D. Yee
City of Hope Medical Center
Interventions
  • Other: Questionnaire Administration — Ancillary studies
  • Drug: White Button Mushroom Extract — Given PO
Study Locations (1 sites)
City of Hope Medical Center, Duarte, California 91010 United States
Eligibility Criteria
Inclusion Criteria: * This study will be conducted in postmenopausal women who have increased risk of breast cancer and high BMI \>= 30 kg/m\^2 * The study population will consist of women with a relative risk of developing breast cancer that is at least \> 2 x that of the general population for their age group based on any of the following: * Have a known genetic mutation associated with hereditary breast cancer (including BRCA1, BRCA2, p53, etc.) * One or more first degree relatives with breast cancer, with at least one under the age of 60 * Two or more second degree relatives with breast cancer, with at least one under the age of 50 * Prior biopsy diagnosing atypical lobular hyperplasia, atypical ductal hyperplasia, lobular carcinoma in situ, or ductal carcinoma in situ in the last 10 years * Have a Gail Risk Assessment (which is based on age, race, age of menarche, age of first live birth, number of first degree relatives with breast cancer, number of breast biopsies, and presence of high risk histology on any biopsies) that is considered high risk compared to the general population i.e. 5 year Gail \>= 1.7 * Prior diagnosis of T1 or T2 breast cancer \>= 5 years, without antiestrogen therapy for \> six months when applicable * ELIGIBILITY CRITERIA FOR HIGH RISK PATIENTS FOR THE CLINICAL TRIAL * Body mass index (BMI) \>= 30 (Asian BMI \>= 25 kg/m\^2) * Postmenopausal, defined as continuous absence of menstruation for 12+ months, status post bilateral oophorectomy, or status post hysterectomy with follicle stimulating hormone (FSH) in menopausal range * Bilateral mammogram within the 12 months prior to study enrollment that is read as not suspicious for breast cancer (American College of Radiology \[ACR\] class I-III). Subjects with a class IV mammogram may be entered once they have had a negative biopsy. In cases of bilateral mastectomy, documentation that the patient has been continuously without evidence of disease for 5 years will suffice * Serum creatinine of 1.5 X upper limit of institutional norm or less * Total bilirubin of 1.5 X upper limit of institutional norm or less * ALT and aspartate aminotransferase (AST) of less than 2 X upper limit of institutional norm or less * Hemoglobin of 9.0 gm/dL or more * Platelets of 100,000/mm\^3 or more * Total white blood cell (WBC) of 3500/mm\^3 * Absolute neutrophil count (ANC) of 1500/mm\^3 or more * Must be willing to have about 40-50 ml of blood (approximately 8-10 teaspoons) drawn at 0 and 3 months * Must be able to swallow pills * This study will assess WBM powder in postmenopausal women of 21 years of age or older. Younger women are unlikely to be postmenopausal * Participants will have Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * The effects of WBM on the developing fetus are unknown. Pregnant and women with childbearing potential are not eligible to participate in this study of postmenopausal women at high risk of breast cancer * All subjects must have the ability to understand and the willingness to sign a written informed consent. Participants must be aware of their increased breast cancer risk and willingly consent after being informed of the investigational nature of the intervention, alternatives, potential benefits, side-effects, risks, and discomforts * Prior therapies, including chemoprevention or adjuvant therapies, must have been completed for 6 or more months prior to study entry. Prior use of mushroom or mushroom chemical-containing supplements must have been completed within 3 months of study entry Exclusion Criteria: * Active malignancy within the past 5 years with the exception of non-melanoma skin cancer or carcinoma in situ of the cervix. NOTE: If there is a history of prior malignancy, the participant must not be receiving other specific treatment, i.e., other hormonal therapy, for their cancer * Ongoing chemotherapy, radiation therapy, or other cancer-related treatment * History of a bleeding tendency or current use of Coumadin or other anticoagulants * Concurrent use of hormone-modifying medications including systemic hormone replacement therapy (local vaginal preparations are permitted), selective estrogen receptor modifiers (SERMs), aromatase inhibitors (Ais), or gonadotropic-releasing hormone (GnRH) modifiers within 3 months of randomization * Concurrent use of immunosuppressant medications * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, hypertension, or psychiatric illness/social situation that would limit compliance with study requirements * Chronic use of any herbal or dietary supplement containing mushrooms within the 3 months prior to entry on the study * Treatment with other investigational agents * Premenopausal status * Known sensitivity or allergic reactions attributed to compounds of similar chemical or biologic composition to WBM or * Subjects on a standing regimen of full dose aspirin (\>= 325 mg/day), nonsteroidal anti-inflammatory drugs (NSAIDs) or NSAID-containing products * Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures * Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study
Conditions Mastectomy; Lymphedema, Breast Cancer, Q...
Phase Not Applicable
Enrollment 528
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a response-adaptive (RAR) prospective randomized study with a long-term follow-up and the aim of this clinical study is to measure with qualitative and quantitative indicators the changes in cosmetic results, quality of life and patient satisfaction after breast reconstructive surgery with silicone implant (following SSM, ASM or NSM mastectomy) and symmetrization (mastopexy and/or silicone implant and/or Ultrapro mesh sling technique) over time. According to the hypothesis of the study, the results of implant-based breast reconstruction and symmetrization following advanced postmastectomy techniques significantly decrease over time and later results limited patient satisfaction rate. This is mainly due to the fact that over time, the natural breast differs from the reconstructed breast with silicone implant. Because of the different biological properties (gravity results ptosis on breast with mastopexy, significant volume increasement of the breast with mastopexy due to endocrine therapy, gradually progressive capsular contracture on the tumorous side, nipple flattening, nipple tattoo fading etc.) the two sides change differently resulting in significant asymmetry and consequently could lead to decreased patient satisfaction. The high degree of asymmetry over time (which can be similar to the difference between the result of a simple mastectomy and natural breast (control group)), may indicates additional surgeries or usage of medical devices, putting a financial burden on the patient and the health system. On the other hand, the symmetry can be achieved with bilateral skin-sparing mastectomies and implant-based immediate or delayed-immediate reconstructions is clearly better and change less with time. The mastectomy of the contralateral disease-free side is considered as an unreasonable burden for moderate risk patients. The information such as the need for multiple surgeries, change in symmetry over time etc., should be an important part of the professional decision-making mechanism and the surgeon should inform the patient during the primer surgery. Nowadays due to the lack of evidence-based knowledge, it is not part of the patient's information and surgical planning internationally. Planning breast units, attention, capacity and financial resources must also be provided to meet the long-term needs of patients who underwent postmastectomy breast reconstruction. Simple mastectomy with an external prosthesis can be an alternative for patients with intolerable degree of asymmetry or on the contrary, the results may justify the need for bilateral mastectomy and reconstruction even in the absence of high oncological risk and for purely symmetrical and cosmetic reasons.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Procedure: A: expander-silicone implant exchange and contralateral symmetrization with mastopexy and if needed with volume reduction — expander-silicone implant exchange and contralateral symmetrization with mastopexy and if needed with volume reduction
  • Procedure: B: expander-silicone implant exchange with contralateral symmetrization with mastopexy and Ultrapro sling — expander-silicone implant exchange with contralateral symmetrization with mastopexy and Ultrapro sling
  • Procedure: C: expander-silicone implant exchange and contralateral symmetrization with mastopexy and silicone implant augmentation — expander-silicone implant exchange and contralateral symmetrization with mastopexy and silicone implant augmentation
  • Procedure: D: expander-silicone implant exchange and contralateral symmetrization with mastopexy and Utrapro sling and silicone implant augmentation — expander-silicone implant exchange and contralateral symmetrization with mastopexy and Utrapro sling and silicone implant augmentation
  • Procedure: E: unilateral simple mastectomy — unilateral simple mastectomy
  • Procedure: F: after bilateral SSM, ASM, NSM, expander-implant exchange — after bilateral SSM, ASM, NSM, expander-implant exchange

Primary Outcomes

  • Quality of life: BREAST-Q validated questionnaire (up to 5 years)
  • Patient satisfaction: BREAST-Q validated questionnaire (up to 5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2020-04-27
Completion: 2027-04-10
Eligibility
Age: 18 Years – 65 Years
Sex: FEMALE
Volunteers: true
Enrollment: 528 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Institute of Oncology, Hungary
Contact Information
Study Contact:
Zoltan Matrai, M.D. Dr. med. habil, PhD
+3612248600
matraidoc@gmail.com
National Institute of Oncology
Zoltan Matrai, M.D. Dr. Habil Ph.D. FEBS
National Institute of Oncology
Mihaly Ujhelyi, M.D. Ph.D. FEBS
National Institute of Oncology
Interventions
  • Procedure: A: expander-silicone implant exchange and contralateral symmetrization with mastopexy and if needed with volume reduction — expander-silicone implant exchange and contralateral symmetrization with mastopexy and if needed with volume reduction
  • Procedure: B: expander-silicone implant exchange with contralateral symmetrization with mastopexy and Ultrapro sling — expander-silicone implant exchange with contralateral symmetrization with mastopexy and Ultrapro sling
  • Procedure: C: expander-silicone implant exchange and contralateral symmetrization with mastopexy and silicone implant augmentation — expander-silicone implant exchange and contralateral symmetrization with mastopexy and silicone implant augmentation
  • Procedure: D: expander-silicone implant exchange and contralateral symmetrization with mastopexy and Utrapro sling and silicone implant augmentation — expander-silicone implant exchange and contralateral symmetrization with mastopexy and Utrapro sling and silicone implant augmentation
  • Procedure: E: unilateral simple mastectomy — unilateral simple mastectomy
Study Locations (1 sites)
National Institute of Oncology, Budapest, 1122 Hungary
Eligibility Criteria
Inclusion Criteria: * Under the age of 65 with uni- or bilateral primary breast cancer ( clinical Stage 0-III), needing modern skin sparing mastectomy, nipple sparing mastectomy or areola sparing mastectomy independently of the axillary surgery, having immediate or delayed-immediate implant based reconstrucion on the ipsilateral side and symmetrisation on the contralateral side ( mastopexy and/or implant based reconstruction and/or breast sling with ultrapro mesh) * Control group: patients under 65 years with unilateral simplex mastectomy without breast reconstruction Exclusion Criteria: * In case the patient does not volunteer for the examination or the follow-ups * Age above 65 years or poor general health condition, where the estimated life expectancies would be less than 2 years even without the tumorous disease * Malignant invasive tumor in the past history (except for non-melanoma skin tumors) * Mastectomyand reconstruction performed due pregnancy associated breast cancer * Prior breast surgery (e.g. aesthetic surgery, mastopexy) and/or radiotherapy on the breast or in the axilla * Malignant tumor is not removed completely with pathological examination * Severe non-surgical (e.g. radiotherapy) complication, which could influence the aesthetic and functional results * Autoimmune diseases * Mastitis carcinomatosa * Lymphangitis carcinomatosa * Open wound therapy due SSI * Long-term steroid usage, which changed the skin's quality and structure * Patient under foster care, or psychically non-cooperative patient * If breast correction performed during the 5 years follow up
Conditions Breast Cancer Survivors, Colorectal (Col...
Phase Not Applicable
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

A metabolic issue is a condition where the body has problems with converting food into energy, using energy or storing energy properly. Examples of metabolic issues include obesity, diabetes, or high blood pressure MASLD -Metabolic-associated steatotic liver disease - also known as non-alcoholic fatty liver disease, is a condition where fat builds up in the liver due to metabolic issues. Excess liver fat can cause inflammation, scaring, also known as fibrosis, and over time, lead to liver failure. MASLD can have different severities. Non-fibrotic MASLD is when there is a small amount of fat in the liver and usually does not cause major problems. However, it can get worse over time and can develop into fibrotic MASLD. MASLD is very common, about one-third of the world's population is affected. In Switzerland, it is predicted that one-quarter of the Swiss population is affected by it. MASLD can affect anyone who has any metabolic issues, however it seems like some medications, such as cancer treatments, could play a role in MASLD development. Studying MASLD is important because it is very common. Learning more about it can help doctors find better ways to diagnose and treat the condition. Furthermore, it is important to find out who would be more likely to develop MASLD. People who are more likely could maybe do some regular testing to diagnose it early and start treatment before it is worsening. Early diagnosis is important since liver damage can be reversed with lifestyle changes, diet or medication. Cancer survivors are at a higher risk of developing MASLD due to changes in their metabolism, lifestyle as well as side effects of cancer treatments. However, MASLD is often underdiagnosed in cancer survivors, even though it can increase the risk of future health complications. Currently, liver biopsy is the standard method of diagnosing MASLD, as it provides the most accurate results. However, liver biopsy is uncomfortable and carries risks like pain and infections. Newer non-invasive technologies, such as ultrasound-based vibration-controlled transient elastography (VCTE, also known as FibroScan®) and Magnetic Resonance Imaging (MRI), show promise in detecting liver fibrosis earlier and more safely. However, they are not yet widely used because they are not as precise as biopsy at detecting liver inflammation. EVALUATE is an observational study performed by the Department of Clinical Research at the University of Bern. In collaboration with the Department of Hepatology, Inselspital, University Hospital of Bern and the Department of Radiology, University Cancer Centre Inselspital. EVALUATE will use two of the newer, less painful methods - VCTE and MRI to check for signs of fibrotic MASLD. Combined with a blood test, a score can be calculated to see if someone is at high-risk for advanced MASLD. In the case that the results from the main study are uncertain, the participant will be asked to participate in an MRI sub study. This study…

Design

Study type: Observational Observational model: Case Only Time perspective: Prospective

Primary Outcomes

  • High probability of fMASLD (Month 3)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-11-14
Completion: 2027-11-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Bern
Collaborators: Insel Gruppe AG, University Hospital Bern
Principal Investigators:
  • Eva Segelov, Prof. (PRINCIPAL_INVESTIGATOR) - Department of Clinical Research, University of Bern
Contact Information
Study Contact:
Study coordinator
+41 79 804 04 05
evaluate.dcr@unibe.ch
Study team
+41 79 804 04 05
evaluate.dcr@unibe.ch
Department of Clinical Research, University of Bern
Interventions
N/A
Study Locations (1 sites)
Department of Clinical Research, University of Bern, Bern, 3010 Switzerland
Eligibility Criteria
Inclusion criteria: * Signed Informed consent form * Age ≥ 18 years * Diagnosis of BC or CRC at least 5 years but no more than 10 years before enrollment, and no recurrence or new cancer diagnoses during this time period (except for superficial non-melanoma skin cancer or superficial bladder cancer or cancer in-situ). Patients who received/are still receiving adjuvant therapy may be included. Time period is calculated from date of first histological diagnosis of cancer. Exclusion criteria: * Known or suspected chronic hepatic disease * Pregnancy, or suspected pregnancy (as liver stiffness and fat content are often elevated but reverse after childbirth) * For the MRI sub-study: Contraindication to MRI, including: claustrophobia and presence of metal implants or devices or foreign metal objects in/on the body, such as pacemakers, defibrillators, prosthetic cardiac valves, cochlear implants, metal clips e.g., vascular clips, spinal cord stimulators or deep brain stimulators, shrapnel or bullet fragments, metal in the eyes, orthopedic hardware and piercings that cannot be easily removed.
Conditions TNBC - Triple-Negative Breast Cancer, Mi...
Phase Not Applicable
Enrollment 422
Locations 14 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

A prospective, multicenter, observational study to evaluate the correlation of Molecular Residual Disease (MRD) detection using circulating tumor DNA guided test to pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in stage I-III triple negative breast cancer (TNBC). Results from this study aim to improve MRD detection and disease outcomes for future patients.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Evaluate the correlation of MRD to pCR after NAC in TNBC (through study completion, an average of 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-11-09
Completion: 2025-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 422 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Personalis Inc.
Principal Investigators:
  • Pavani Chalasani (PRINCIPAL_INVESTIGATOR) - George Washington University
Contact Information
Study Contact:
Soumya Chappidi
484-704-2599
schappidi@criteriuminc.com
Julee Hartwell
607-651-6273
jhartwell@criteriuminc.com
Stacey Kimbell
520-668-5678
stacey.kimbell@usoncology.com
Arizona Oncology
Interventions
N/A
Study Locations (14 sites)
Arizona Oncology, Tucson, Arizona 85704 United States
University of Colorado Cancer Center, Aurora, Colorado 80045 United States
George Washington University, Washington D.C., District of Columbia 20037 United States
Mount Sinai Medical Center of Florida, Miami Beach, Florida 33140 United States
Comprehensive Hematology Oncology (ONare Alliance, LLC / Exigent Research, LLC, St. Petersburg, Florida 33709 United States
Illinois Cancer Care, Peoria, Illinois 61615 United States
Louisiana State University, New Orleans, Louisiana 70112 United States
Trinity Health-Michigan, Ypsilanti, Michigan 48197 United States
Nebraska Methodist, Omaha, Nebraska 68114 United States
Stony Brook University Cancer Center, Stony Brook, New York 11794 United States
Eligibility Criteria
Inclusion Criteria: 1. Have histologically documented TNBC (defined as ER expression ≤10% by IHC, PR expression≤10% by IHC and HER2 0 or 1+ by IHC or FISH ratio \<2 or HER2 gene copy number of \<6). 2. Early-stage breast cancer (stage I-III) and scheduled to undergo NAC treatment with curative intent. 3. Be informed of the investigational nature of the study and all pertinent aspects of the trial. 4. Have the ability to understand and the willingness to sign a written informed consent document in accordance with institutional and federal guidelines. 5. Be ≥ 18years of age. 6. Patient who are scheduled to start NAC. 7. Be willing to provide blood samples before and during treatment. 8. Have available biopsy tissue. Exclusion Criteria: 1. Receiving concurrent anti-neoplastic therapy for another malignancy. 2. Stage IV disease. 3. Current or history of another primary cancer within 5 years of study entry, with the exception of basal or squamous cell skin cancer, or non-invasive malignancy. 4. History of allogeneic bone marrow or organ transplant. 5. Blood transfusion within two weeks before collection of blood for central ctDNA testing. 6. Started systemic therapy for their breast cancer. 7. Pregnancy
Conditions Liposarcoma, Prostate Cancer, Advanced B...
Phase PHASE1, PHASE2
Enrollment 430
Locations 39 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a Phase 1/2A, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 administered as a single agent and in combination with endocrine therapy. Part 1 includes dose escalation cohorts evaluating PF-07220060 as single agent or in combination with endocrine therapy or enzalutamide, as well as a food effect cohort and a DDI cohort. Part 2 includes dose expansion cohorts evaluating PF-07220060 in combination with endocrine therapy or enzalutamide. The Giredestrant Combination Cohort will evaluate PF-07220060 in combination with giredestrant. In Part 1A, single escalating doses of PF-07220060 alone will be administered to determine the maximum tolerated dose (MTD) and select the recommended dose for expansion. In Part 1B and Part 1C, PF-07220060 will be administered in combination with 1 of 2 endocrine therapies (letrozole and fulvestrant, respectively). In Part 1D, food effect assessment of PF-07220060 at the RP2D dose level from Part 1A will be conducted. In Part 1E, the effect of PF-07220060 on the PK of midazolam will be evaluated (DDI). In Part 1F, escalating doses of PF-07220060 will be administered in combination with enzalutamide. In Part 1G, PF-07220060 will be administered in combination with tamoxifen to determine the RDE. Part 2A is an expansion cohort for PF-07220060 in combination with fulvestrant and will explore more than one dose of PF-07220060. Part 2B and Part 2C are expansion cohorts for PF-07220060 in combination with letrozole and fulvestrant, respectively. Part 2E is an expansion cohort to evaluate PF-07220060 Monotherapy versus PF-07220060 plus fulvestrant combination therapy. Part 2F is an expansion cohort for PF-07220060 in combination with tamoxifen. The Giredestrant Combination Cohort Group A will determine the tolerable dose of PF-07220060 in combination with giredestrant. In Group B, additional participants will be enrolled at the tolerable dose to further assess safety and PK. The China and Japan monotherapy cohorts will evaluate safety, tolerability, and PK of PF-07220060 as single agent in Chinese and Japanese participants, respectively.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: PF-07220060 — CDK4 inhibitor
  • Combination Product: Letrozole — Endocrine Therapy
  • Combination Product: Fulvestrant — Endocrine Therapy
  • Other: Midazolam — Benzodiazepine
  • Combination Product: Enzalutamide — Androgen Receptor inhibitor
  • Combination Product: Giredestrant — Endocrine Therapy
  • Combination Product: Tamoxifen — Endocrine Therapy

Primary Outcomes

  • Number of participants with dose limiting toxicities in the Dose Escalation or De-escalation Portion (At the end of Cycle 1 (each cycle is 28 days))
  • Incidence of clinically significant AEs (Cycle 1 (each cycle is 28 days) through study completion, up to approximately 24 months)
  • Incidence of clinically significant laboratory assessments (Cycle 1 (each cycle is 28 days) through study completion, up to approximately 24 months)
  • Incidence of clinically significant abnormal vital and ECG parameters (Cycle 1 (each cycle is 28 days) through study completion, up to approximately 24 months)
  • Maximal Plasma Concentration (Cmax) of PF-07220060 given with and without food (Cycle 1 (each cycle is 28 days))
  • Time to Maximum Plasma Concentration (Tmax) of PF-07220060 given with and without food (Cycle 1 (each cycle is 28 days))
  • Area Under the Plasma Concentration Versus Time Curve from Time Zero to the Last Sampling Time Point (AUClast) of PF-07220060 given with and without food (Cycle 1 (each cycle is 28 days))
  • Maximal Plasma Concentration (Cmax) of Midazolam with and without PF-07220060 (Cycle 1 (each cycle is 28 days))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2020-09-23
Completion: 2029-10-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 430 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Pfizer
Principal Investigators:
  • Pfizer CT.gov Call Center (STUDY_DIRECTOR) - Pfizer
Contact Information
Study Contact:
Pfizer CT.gov Call Center
1-800-718-1021
ClinicalTrials.gov_Inquiries@pfizer.com
Interventions
  • Drug: PF-07220060 — CDK4 inhibitor
  • Combination Product: Letrozole — Endocrine Therapy
  • Combination Product: Fulvestrant — Endocrine Therapy
  • Other: Midazolam — Benzodiazepine
  • Combination Product: Enzalutamide — Androgen Receptor inhibitor
Study Locations (39 sites)
Ellison Institute, Los Angeles, California 90064 United States
Smilow Cancer Hospital - Yale New Haven Health, New Haven, Connecticut 06510 United States
Yale-New Haven Hospital-Yale Cancer Center, New Haven, Connecticut 06510 United States
Smilow Cancer Hospital Phase 1 Unit, New Haven, Connecticut 06511 United States
Yale University - Smilow Cancer Hospital; C/O Thomas Ferencz, RPh, BCOP, New Haven, Connecticut 06511 United States
Smilow Cancer Hospital - Trumbull, Trumbull, Connecticut 06611 United States
Brigham & Women's Hospital, Boston, Massachusetts 02115 United States
Dana-Farber Cancer Institute, Boston, Massachusetts 02215 United States
Dana Farber Cancer Institute- Chestnut Hill, Newton, Massachusetts 02467 United States
START Midwest, Grand Rapids, Michigan 49546 United States
Eligibility Criteria
Inclusion Criteria * Part 1: Breast Cancer (BC) * Refractory Hormone Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) BC * Part 1A/Part 1D/Part 1E also include: Refractory HR-positive/HER2-positive BC * Part 1: Tumors other than BC (Part 1A/Part 1D/Part 1E): NSCLC, prostate, CRC, liposarcoma, or tumors with previously confirmed CDK4 or CCND1 amplification according to local standard tests * Part 1F: prostate cancer * Part 1G: HR-positive/HER2-negative BC * Part 2A, 2B, 2C, 2E, and 2F: HR-positive/HER2-negative BC * Part 1D: metastatic castration resistant prostate cancer * Giredestrant Combination Cohort: ER-positive/HER2-negative BC * Prior systemic Treatment * Part 1: HR-positive/HER2-negative BC * At least 1 line of SOC, including CD4/6 inhibitor therapy for advanced or metastatic disease, or if CDK4/6 inhibitors are not considered appropriate in the opinion of the investigator * HR-positive/HER2-positive BC (Parts 1A/1D/1E): at least 1 prior treatment of approved HER2 targeting therapy * Tumors other than BC (Parts 1A/1D/1E/1F): tumor that is resistant to at least 2 lines of SOC for advanced or recurrent disease or for which no standard therapy is available * Part 2A and 2E: at least 1 line of standard of care (including prior CDK4/6i) for advanced/metastatic disease; Prior chemo is allowed; Prior fulvestrant, mTOR and/or PI3K inhibitors are allowed * Part 2B: no prior systemic anti-cancer therapies for advanced/metastatic BC * Part 2C: * Progressed during treatment or within 12 months of completion of adjuvant therapy with an aromatase inhibitor if postmenopausal, or tamoxifen if pre or perimenopausal, or * Progressed while on or within 1 month after the endo the prior aromatase inhibitor therapy for advanced/metastatic BC if postmenopausal or prior endocrine treatment for advanced/metastatic BC if pre or perimenopausal * One previous line of chemotherapy for advanced/metastatic disease is allowed in addition to endocrine therapy * Part 1G and 2F: at least 2 lines of SOC for advanced or metastatic disease, including CDK4/6 inhibitor and endocrine therapy * Giredestrant Combination Cohort: at least 1 (no more than 3) prior line(s) of SOC for advanced or metastatic disease, including CDK4/6 inhibitor and endocrine therapy General Inclusion Criteria * All participants must be refractory to or intolerant of existing therapies known to provide clinical benefit for their condition. * Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1 * Adequate renal, liver, and bone marrow function Exclusion Criteria: * Part 2B: prior neoadjuvant or adjuvant treatment with a non-steroidal aromatase inhibitor with disease recurrence while on or within 12 months of completing treatment. Prior treatment with any CDK4/6 inhibitor * Part 2C: prior treatment with any CDK inhibitor, fulvestrant, everolimus, or any agent whose mechanism of action is to inhibit the PI3K-mTOR pathway * Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases carcinomatous meningitis, or leptomeningeal disease * Other active malignancy within 3 years prior to randomization, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ * Major surgery or radiation within 4 weeks prior to study intervention * Last anti-cancer treatment within 2 weeks prior to study intervention; Part 1G and 2F: tamoxifen treatment within 35 days of Day -4 * Participation in other studies involving investigational drug(s) within 4 weeks prior to study entry * Part 1G and 2F: history of or current pulmonary embolism or deep vein thrombosis * Giredestrant Combination Cohort: history (within 6 months of screening) of or presence of idiopathic symptomatic bradycardia or resting heart rate \<50 bpm at screening * Pregnant or breastfeeding female participant * Active inflammatory gastrointestinal (GI) disease, known diverticular disease or previous gastric resection or lap band surgery including impairment of gastrointestinal function or GI disease
Conditions Breast Cancer
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

Chemotherapy-associated side-effects would affect therapeutic effect, quality of life, and cause permanent harm to breast cancer patients. This study is designed to explore after consumption of probiotics of lactobacillus composite strain powder sachets for 6 months in breast cancer chemotherapy, and whether the improvement of meliorate the side effects, further assists patients completing the chemotherapy.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Double

Interventions / Regimen

  • Dietary Supplement: Probiotic — Three-strain probiotic supplement includes Lactobacillus reuteri GMNL-89 (alive), Lactobacillus plantarum GMNL-141 (alive) and Lactobacillus paracasei GMNL-133 (alive).
  • Other: Placebo — Same additives to Probiotic group but replace probiotics with corn starch and Maltodextrin.

Primary Outcomes

  • Change from 12 weeks in the chemotherapy associated side-effects questionnaire at 24 weeks (24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-04-08
Completion: 2026-12-31
Eligibility
Age: 20 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: GenMont Biotech Incorporation
Collaborators: Mackay Memorial Hospital
Principal Investigators:
  • Po-Sheng Yang, MD, PhD (PRINCIPAL_INVESTIGATOR) - Mackay Memorial Hospital
Contact Information
Study Contact:
Fang-Kuei Lin, Master
+886-6-505-2151
meitung@genmont.com.tw
Wan-Hua Tsai, PhD
+886-6-505-2151
twh@genmont.com.tw
Po-Sheng Yang, MD, PhD
Mackay Memorial Hospital
Interventions
  • Dietary Supplement: Probiotic — Three-strain probiotic supplement includes Lactobacillus reuteri GMNL-89 (alive), Lactobacillus plantarum GMNL-141 (alive) and Lactobacillus paracasei GMNL-133 (alive).
  • Other: Placebo — Same additives to Probiotic group but replace probiotics with corn starch and Maltodextrin.
Study Locations (1 sites)
Mackay Memorial Hospital, Taipei, Taiwan
Eligibility Criteria
Inclusion Criteria: * Stage I-III breast patients using anthracycline-based and taxane-based chemotherapy (not limited before or after chemotherapy/surgery) * BMI \> 18 kg/m\^2 * Age between 20 and 80 years old * Patients judged by physicians to participate in this trial and who are willing Exclusion Criteria: * Pregnant or lactating female patients * Patients with bariatric surgery, gastrointestinal resections, Crohn's disease, celiac disease * BMI \< 18 kg/m\^2 * Patient who have severe allergy to soybeans or peanuts * Those who are under 20 years old or over 80 years old
Conditions Breast Cancer, Colorectal Cancer
Phase NA
Enrollment 174
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

This two-stage adaptive randomized controlled trial evaluates the feasibility and preliminary efficacy of large language model (LLM)-assisted intervention for managing chemotherapy side effects in patients with solid tumors. Adults with histologically confirmed breast or colorectal cancer scheduled for at least 3 months of systemic chemotherapy will be randomly assigned (1:1) to receive either LLM-assisted care or standard care. The study employs an adaptive design with initial enrollment of 60 patients (30 per arm), followed by interim analysis. Unless enrollment is stopped for safety reasons identified at interim analysis, an additional 114 patients will be enrolled for a maximum total of 174 patients (87 per arm). In the intervention group, healthcare providers input anonymized patient symptom data into an LLM system using sessions where data is not retained, which generates evidence-based management recommendations. Physicians critically review these recommendations and use them as reference for clinical decision-making, with final treatment decisions remaining under physician discretion. The control group receives standard supportive care without LLM assistance. The primary outcome is change in health-related quality of life measured by EORTC QLQ-C30 global health status/QoL scale from baseline to end of treatment. Secondary outcomes include proportion achieving clinically meaningful improvement (≥8-point increase), treatment adherence, dose intensity, healthcare resource utilization, and physician acceptance of LLM recommendations.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Double

Interventions / Regimen

  • Behavioral: LLM-assisted chemotherapy side effect management — Healthcare providers collect patient symptoms during clinic visits, anonymize the information, and input it into the LLM system via temporary chat sessions. The LLM generates management recommendations which physicians review and consider when adjusting treatment plans. Healthcare providers anonymize patient information and input into LLM using temporary chat sessions. LLM recommendations serve as reference only, with physicians making all final clinical decisions.

Primary Outcomes

  • Change in health-related quality of life measured by EORTC QLQ-C30 global health status/QoL scale (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 - Global Health Status/Quality of Life Scale) (Baseline, mid-treatment, end of treatment, 3 months post-treatment (up to 9 months))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-11-12
Completion: 2026-10-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 174 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Incheon St.Mary's Hospital
Contact Information
Study Contact:
Young-Joon Kang
+82322805179
yjkang.md@gmail.com
Young Joon Kang
82-32-280-5179
yjkang.md@gmail.com
Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea
Interventions
  • Behavioral: LLM-assisted chemotherapy side effect management — Healthcare providers collect patient symptoms during clinic visits, anonymize the information, and input it into the LLM system via temporary chat sessions. The LLM generates management recommendations which physicians review and consider when adjusting treatment plans. Healthcare providers anonymize patient information and input into LLM using temporary chat sessions. LLM recommendations serve as reference only, with physicians making all final clinical decisions.
Study Locations (1 sites)
Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, 21431 South Korea
Eligibility Criteria
Inclusion Criteria: * Adult patients (≥ 18 years old) diagnosed with histologically confirmed solid malignancies (breast cancer, colorectal cancer) * Patients scheduled to receive at least 3 months of systemic chemotherapy * ECOG performance status 0-2 Exclusion Criteria: * Severe psychiatric disorders * Cognitive impairment affecting ability to report symptoms * Presence of cancer-related symptoms prior to chemotherapy initiation * Concurrent participation in trials evaluating other symptom management interventions Inability to provide informed consent Life expectancy less than 6 months
Conditions Breast Cancer With Low to Intermediate H...
Phase NA
Enrollment 35
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

Breast cancer is the commonest cancer affecting women worldwide. Early breast cancer is treated surgically with wide local excision of tumor with axillary staging operations like sentinel node biopsy. Surgical adjuncts used in identifying and localizing the area for excision include metallic wire, radioactive or magnetic seeds and radiofrequency reflectors. These are placed in the lesion under image guidance by the breast radiologists, either on the day of surgery (wires) or prior (seeds). Bracketing localization is performed in case of multiple lesions or wide spread calcifications to aid the surgeons in performing wide local excision of all involved areas. This means placing multiple devices around the area of excision for accurate triangulation, which increase the costs significantly. Localization agents like radionucleotide labelled albumin, super paramagnetic iron oxide (SPIO) and colored dyes like methylene blue, isosulphane blue and indocyanine green are injected in the breast for identification of sentinel lymph nodes in the axilla. More recent studies have demonstrated successful use of SPIO in localization of small impalpable breast cancer lesions. This also raises the prospect of using SPIO for the dual purpose of lesion localization / bracketing and sentinel node biopsy. This study was designed to test this principle in patients requiring bracketing. This is a prospective proof-of-concept pilot study to evaluate the feasibility of SPIO (Magtrace®) as a single-agent solution for bracketing the excision area and localizing the sentinel lymph node for breast-conserving surgery. Patients with breast cancer requiring bracketing and sentinel node biopsy will be identified through multidisciplinary breast tumor board and invited to take part in the study. All patients who consent to participate will receive an injection of Magtrace® for bracketing (0.5ml each at four points around the excision area) one day before surgery under ultrasound guidance. Primary outcome will be successful localization of the Magtrace® signal in breast for bracketing and in the sentinel node, using a magnetic probe on the day of surgery. Clinical outcomes, complications and cost analyses will be performed as secondary outcomes. We anticipate a sample size of 35 patients to be recruited for the study.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Super paramagnetic iron oxide bracketing injection — Lesion localization procedure will be performed one day before or on the day of surgery. Patients included in the study will have localization of primary cancer / cancers with Magseed® and bracketing with Magtrace® under ultrasound / Mammographic guidance as indicated, in accordance with the local treatment protocol. The Consultant Radiologist using Magtrace® will perform bracketing under image guidance. 0.5ml of Magtrace® will be injected into the breast parenchyma superior, inferior, medial and lateral to the area planned for excision.

Primary Outcomes

  • Success localization of bracketing Magtrace injection with Magnetic probe (Morning of surgery.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-07-24
Completion: 2029-08-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 35 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: King Faisal Specialist Hospital & Research Center
Principal Investigators:
  • Fayyaz A Mazari, MBBS, MSc, MS, PhD, FRCS, FEBS (PRINCIPAL_INVESTIGATOR) - King Faisal Specialist Hospital & Research Center
Contact Information
Study Contact:
Fayyaz A Mazari, MBBS, MSc, MS, PhD, FRCS, FEBS
+966 12667 7777
fmazari@kfshrc.edu.sa
Zabihullah Khan, MBBS FRCS
+966126677777
zkhan@kfshrc.edu.sa
Fayyaz A Mazari, MBBS, MSc, MS, PhD, FRCS, FEBS
+966 12667 7777
fmazari@kfshrc.edu.sa
King Faisal Specialist Hospital and Research Center
Interventions
  • Other: Super paramagnetic iron oxide bracketing injection — Lesion localization procedure will be performed one day before or on the day of surgery. Patients included in the study will have localization of primary cancer / cancers with Magseed® and bracketing with Magtrace® under ultrasound / Mammographic guidance as indicated, in accordance with the local treatment protocol. The Consultant Radiologist using Magtrace® will perform bracketing under image guidance. 0.5ml of Magtrace® will be injected into the breast parenchyma superior, inferior, medial and lateral to the area planned for excision.
Study Locations (1 sites)
King Faisal Specialist Hospital and Research Center, Madinah, Saudi Arabia
Eligibility Criteria
Inclusion Criteria: All patients with breast cancer undergoing breast conserving surgery requiring bracketing of the area of excision (as determined by the multidisciplinary tumor board) and a sentinel lymph node biopsy for axillary staging. Exclusion Criteria: 1. Patients having mastectomy. 2. Patients unfit for breast conserving surgery due to inability to have adjuvant radiotherapy. 3. Patients requiring axillary clearance without sentinel node biopsy. 4. Patient undergoing breast conserving surgery without need for sentinel node biopsy. 5. Patient with metastatic breast cancer requiring palliative surgery for local control. 6. Patients not consenting for research. 7. Patient with allergy to Magtrace.
Conditions Anatomic Stage I Breast Cancer AJCC v8, ...
Phase Not Applicable
Enrollment 1300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

This study collects blood samples as well as clinical and self-report data from stage I-III breast cancer survivors to create a biorepository for future use. The creation of this biorepository will allow for future research into links between individual, molecular, and genomic signatures and cancer outcomes.

Design

Study type: Observational Observational model: Case Only Time perspective: Prospective

Interventions / Regimen

  • Procedure: Biospecimen Collection — Undergo collection of blood samples
  • Other: Electronic Health Record Review — Review of records
  • Other: Quality-of-Life Assessment — Complete quality-of-life questionnaires
  • Other: Survey Administration — Complete surveys

Primary Outcomes

  • Biorepository (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-04-11
Completion: 2028-04-11
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 1300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Southern California
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Bodour Salhia, PhD (PRINCIPAL_INVESTIGATOR) - University of Southern California
Contact Information
Study Contact:
Audrey Saghian, MPH
323-865-6086
amsaghia@usc.edu
Audrey Saghian, MPH
323-865-6086
Amsaghia@usc.edu
USC / Norris Comprehensive Cancer Center
Bodour Salhia, PhD
USC / Norris Comprehensive Cancer Center
Interventions
  • Procedure: Biospecimen Collection — Undergo collection of blood samples
  • Other: Electronic Health Record Review — Review of records
  • Other: Quality-of-Life Assessment — Complete quality-of-life questionnaires
  • Other: Survey Administration — Complete surveys
Study Locations (1 sites)
USC / Norris Comprehensive Cancer Center, Los Angeles, California 90033 United States
Eligibility Criteria
Inclusion Criteria: * Women of all racial and ethnic groups 18 years of age or older * Women with a diagnosis of invasive breast cancer (stages I-III) within the past 7 years * Women who have completed active treatment for breast cancer (surgery, chemotherapy, HER2-directed therapy and radiation) * Prior participation on clinical trials is allowed Exclusion Criteria: * Current receipt of interventional clinical trial participation * Stage IV (metastatic) cancer * Prior history of recurrence (except recurrence following ductal carcinoma in situ) * Inability to give informed consent * Unable to speak English, Spanish, Chinese, or Korean
Conditions Breast Cancer
Phase Not Applicable
Enrollment 500
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

The objective of this non-interventional study (NIS) is to evaluate prevalence of ESR1 mutation after endocrine therapy in the palliative setting, quality of life, tolerability, and safety and to describe treatment detail and adverse event (AE) management in postmenopausal women with locally advanced and/or metastatic ER+ HER2- ESR1-mutated breast cancer and second line treatment with elacestrant according to SmPC (Summary of product characteristics) in a real-world setting.

Design

Study type: Observational Observational model: Case Only Time perspective: Prospective

Interventions / Regimen

  • Drug: Elacestrant — According to the Summary of Product Characteristics (SmPC)
  • Drug: Standard of care (Investigator Choice) — Treatment decision of investigator

Primary Outcomes

  • Change from baseline in EORTC global health scale (From Time of enrollment until month 11)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-06-19
Completion: 2028-06
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: iOMEDICO AG
Collaborators: Berlin Chemie AG
Principal Investigators:
  • Thomas Decker, Professor (PRINCIPAL_INVESTIGATOR) - Gemeinschaftspraxis für Hämatologie und Onkologie GbR Ravensburg
  • Michael Patrick Lux, Professor (PRINCIPAL_INVESTIGATOR) - St. Louise Frauen- und Kinderklinik Paderborn
Contact Information
Study Contact:
Laura Serrer
+49761152420
eleni@iomedico.com
Patrick Marschner
+49761386870
klifo@onkologie-freiburg.de
Praxis für interdisziplinäre Onkologie & Hämatologie
Michael P Lux
+49 5251864121
M.Lux@vincenz.de
St. Louise Frauen- und Kinderklinik
Interventions
  • Drug: Elacestrant — According to the Summary of Product Characteristics (SmPC)
  • Drug: Standard of care (Investigator Choice) — Treatment decision of investigator
Study Locations (3 sites)
Praxis für interdisziplinäre Onkologie & Hämatologie, Freiburg im Breisgau, 79110 Germany
St. Louise Frauen- und Kinderklinik, Paderborn, 33098 Germany
Gemeinschaftspraxis für Hämatologie und Onkologie, Ravensburg, 88212 Germany
Eligibility Criteria
Inclusion Criteria: * Signed and dated informed consent form * Postmenopausal women * Age ≥18 years * Eastern Cooperative Oncology Group Performance Status (ECOG) \< 2 * Locally advanced and/or metastatic ER+ HER2- breast cancer * Histologically proven ER positivity (defined as ≥1% staining by immunohistochemistry (IHC)) * Histologically proven HER2 negativity (defined as a IHC0 or IHC1+ score by IHC or a negative result by in situ hybridization (ISH), optionally combined with a IHC2+ score) * Disease progression following first line ET + CDKi * No more than one prior ET line in the advanced/metastatic setting and intention for 2nd-line treatment with elacestrant according to current elacestrant SmPC as assessed by the treating physician (ESR1 testing can be done after inclusion) * For patients with proven ESR1mut: Study inclusion the latest 2 weeks after start of elacestrant treatment Exclusion Criteria * Prior chemotherapy in the advanced/metastatic setting * Contraindications according to elacestrant SmPC, except for ESR1 test result for patients included prior to ESR1 testing. * Participation in an interventional clinical trial within 30 days prior to enrolment or simultaneous participation in an interventional clinical trial (except follow-up phase)